Wright Investors Service Inc. Sells 4,517 Shares of AbbVie Inc. $ABBV

Wright Investors Service Inc. reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 22.9% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,248 shares of the company’s stock after selling 4,517 shares during the quarter. AbbVie accounts for about 1.0% of Wright Investors Service Inc.’s investment portfolio, making the stock its 25th biggest holding. Wright Investors Service Inc.’s holdings in AbbVie were worth $3,531,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Marshall & Sullivan Inc. WA purchased a new position in AbbVie in the 2nd quarter worth approximately $25,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the 2nd quarter worth $26,000. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie in the second quarter worth $28,000. Financial Gravity Companies Inc. bought a new position in shares of AbbVie during the second quarter valued at $36,000. Finally, Delos Wealth Advisors LLC purchased a new stake in shares of AbbVie during the second quarter valued at $39,000. Institutional investors own 70.23% of the company’s stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research raised AbbVie EPS estimates across multiple quarters and lifted FY2026 and FY2027 forecasts (small but consistent upward revisions), indicating analysts see stronger earnings ahead. (Zacks updates)
• Positive Sentiment: Pipeline and clinical progress: AbbVie reported completion of early human/Phase 1 work on ABBV‑CLS‑616 and on GUB014295 (obesity), which derisks parts of the pipeline and supports future growth potential. ABBV‑CLS‑616 phase 1 update GUB014295 trial completion
• Positive Sentiment: Business development and strategy: partnerships (e.g., RemeGen bispecific antibody) and management commentary at JPM underscore management’s push into oncology and obesity as key growth engines. RemeGen partnership Obesity market buildout
• Positive Sentiment: Large call-option buying (≈478k calls in one session) signals aggressive bullish bets from traders; this can amplify upside moves but also raise volatility and gamma risk for holders.
• Neutral Sentiment: Management reiterated a long-term growth story at JPM and features in industry write-ups highlight AbbVie’s pivoted pipeline strategy — useful context for long-term investors but not immediately market-moving. JPM presentation transcript
• Negative Sentiment: Shares have pulled back today (intraday/close weakness vs. broader market). Short-term pressure appears driven by profit-taking and the stock’s rich valuation (reported P/E ~164), which makes investors sensitive to any near-term miss or rotation away from growth names. Zacks: stock dips while market gains

Analyst Ratings Changes

ABBV has been the subject of a number of recent analyst reports. Guggenheim boosted their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research report on Thursday. Finally, Morgan Stanley boosted their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $247.84.

AbbVie Trading Down 2.4%

Shares of ABBV stock opened at $216.66 on Friday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market cap of $382.91 billion, a P/E ratio of 164.13, a P/E/G ratio of 0.91 and a beta of 0.36. The company has a 50 day simple moving average of $226.89 and a two-hundred day simple moving average of $216.08.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the company posted $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s dividend payout ratio is presently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.